Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo- and vedolizumab-controlled study of UTTR1147A in moderate to severe ulcerative colitis
MOH_2018-09-16_003654Phase 2Recruiting
- Sponsor
- Genentech
- Start
- Feb 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of efmarodocokin alfa in autoimmune colitis (5 arms), sponsored by Genentech. Started Feb 2018; status: recruiting.
02
Drugs
efmarodocokin alfa
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2018-09-16_003654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-09-16_003654.